2 months ago
NBIX
AnalystsJeffrey WalchJeffrey Walch's Stock Forecasts
AnalystsJeffrey Walch
Sectors:
Analyst Ranking
Top 49%
#2606 out of 5327 analysts
Average Return
+16.73%
Win Rate
100%3 out of 3
Risk vs Reward
Poor
Good
Jeffrey Walch's 5 best and worst ratings
Jeffrey Walch Analyst Color
Get additional color on Jeffrey Walch's coverage of popular stocks
2 months ago
JAZZ
Jeffrey Walch's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Nuvalent IncNUVL | 2 | Hold | $124.00 | +0.03% | Downgrades | a month ago |
Neurocrine Biosciences IncNBIX | 1 | Buy | $221.00 | +27.75% | Initiates Coverage On | 2 months ago |
Incyte CorpINCY | 1 | Hold | $99.00 | -14.40% | Initiates Coverage On | 2 months ago |
Jazz Pharmaceuticals PLCJAZZ | 1 | Hold | $229.00 | -5.94% | Initiates Coverage On | 2 months ago |
Revolution Medicines IncRVMD | 1 | Hold | $151.00 | -16.29% | Initiates Coverage On | 2 months ago |
Biontech SeBNTX | 1 | Hold | $96.00 | +4.17% | Initiates Coverage On | 2 months ago |
Summit Therapeutics IncSMMT | 1 | Sell | $7.70 | -42.96% | Initiates Coverage On | 2 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.